6535 Share Price Performance
NT$184.50
-11.50 (-5.87%)
Price NT$184.50
Share Pricen/a
Lumosa Therapeutics Co., Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
6535 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Lumosa Therapeutics Co., Ltd. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -2.57
- 54.16%
- -1,017.70%
- 0%
About 6535
- Founded
- 2000
- Employees
- 43
- CEO
- WebsiteView website
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
